OCI Acquires 11% Stake in Bukwang Pharm for 146.1 Billion KRW, Becomes Largest Shareholder
[Asia Economy Reporter Kwon Jae-hee] OCI announced on the 22nd that it will acquire 7,730,334 shares held by Chairman Kim Dong-yeon, the largest shareholder of Bukwang Pharm, and 9 other related parties for 146.1 billion KRW.
This corresponds to 6.12% of OCI's equity capital.
With this acquisition, OCI's shares in Bukwang Pharm will increase to 7,747,934 shares, raising its stake to 10.90%.
OCI stated, "The acquisition was made to expand our entry into the bio business."
Hot Picks Today
!["Versatile Player Set to Reach 1.7 Million Won: The Company Building the Eyes, Brain, and Neural Network of Autonomous Vehicles [Weekend Money]"](https://cwcontent.asiae.co.kr/asiaresize/93/2024122609475066041_1735174070.png)
"Versatile Player Set to Reach 1.7 Million Won: The Company Building the Eyes, Brain, and Neural Network of Autonomous Vehicles [Weekend Money]"
- "Drive Supercars With Your Own Money... Light Green Plates Now a Trend, Clear Tax Evasion," Says National Tax Service Chief
- "Looking for a Samsung or SK hynix Spouse Instead of a Doctor"... Semiconductor Bonuses Shake Up the Marriage Market
- "If You Miss Sleep, Make Up for It the Next Day"... Risk of Death Soars by Up to 42% Without Compensation
- "Mom, Shall We Take a 'Hotel Staycation' at Grandma's? A Grandparents' Home Where Three Generations Gather Comfortably Without Worrying About Meals or Cleaning [Report]"
The scheduled date for the stock acquisition is March 8.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
